Abstract
Portal hypertension and ascites are two crucial events in the natural history of liver
cirrhosis, whose appearance marks a downward shift in the prognosis of the disease.
Over the years, several international and national societies have issued clinical
practice guidelines for the diagnosis and management of portal hypertension and ascites.
The present document addresses the needs of an updated guidance on the clinical management
of these conditions. Accordingly, the AISF Governing Board appointed a multi-disciplinary
committee of experts for drafting an update of the most recent EASL Clinical Practice
Guidelines. The aim of this work was to adapt the EASL recommendations to national
regulations and resources, local circumstances and settings, infrastructure, and cost/benefit
strategies to avoid duplication of efforts and optimize resource utilization. The
committee defined the objectives, the key issues and retrieved the relevant evidence
by performing a systematic review of the literature. Finally, the committee members
(chosen on the basis of their specific expertise) identified the guidelines’ key questions
and developed them following the PICO format (Population, Intervention, Comparison,
Outcomes). For each of the PICO questions, the systematic review of the literature
was made on the most important scientific databases (Pubmed, Scopus, Embase)
Keywords
Abbreviations:
ACLF (Acute-on-chronic liver failure), AKD (Acute kidney disease), AKI (Acute kidney Injury), ALD (Alcohol-related liver disease), AVB (Acute esophageal variceal bleeding), BT (Bacterial translocation), CACLD (Compensated advanced chronic liver disease), CKD (Chronic kidney disease), CPGs (High-quality clinical practice guidelines), CSPH (Clinically significant PH), CTP (Child-Turcotte-Pugh), DAAs (Direct antiviral agents), GOV (Gastro-oesophageal varices), HVPG (Hepatic venous pressure gradient), ICA (International Club of Ascites), IGV (Isolated gastric varices), LSM (Liver stiffness measurement), LT (Liver transplantation), MELD (Model for End-Stage Liver Disease), NSBBs (Non-selective beta-blockers), PH (Portal hypertension), PLT (Platelet count), PVT (Portal vein thrombosis), RRT (Renal replacement therapy), SBP (Spontaneous bacterial peritonitis), sCr (Serum creatinine), SLK (Simultaneous liver kidney transplantation), SVR (Sustained virologic response), TE (Transient elastography), VH (Variceal hemorrhage), VNT (Varices needing prophylactic treatment), VKA (Vitamin K antagonist)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol. 2018; 69: 406-460
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol. 2010; 53: 397-417
- Adaptation of clinical guidelines: literature review and proposition for a framework and procedure.Int J Qual Health Care. 2006; 18: 167-176
- Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation.BMJ Qual Saf. 2011; 20: 228-236
- Adapting clinical practice guidelines to local context and assessing barriers to their use.CMAJ. 2010; 182: E78-E84
- The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.Hepatology. 2006; 43: S121-S131
- Cirrhosis regression and subclassification.Surg Pathol Clin. 2013; 6: 295-309
- Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.Hepatology. 2016; 63: 197-206
- Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.J Hepatol. 2006; 44: 217-231
- Incidence and natural history of small esophageal varices in cirrhotic patients.J Hepatol. 2003; 38: 266-272
- Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients.Aliment Pharmacol Ther. 2014; 39: 1180-1193
- Natural history of cirrhotic patients with small esophageal varices: a prospective study.Am J Gastro. 2000; 95: 503-508
- Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension.J Hepatol. 2000; 33: 846-852
- A MELD-based model to determine risk of mortality among patients with acute variceal bleeding.Gastroenterology. 2014; 146: 412-419
- Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators.Hepatology. 2003; 38: 599-612
- Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis.Hepatology. 1997; 25: 63-70
- Pharmacological treatment of portal hypertension: an evidence-based approach.Semin Liver Dis. 1999; 19: 475-505
- Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.Liv Int. 2012; 32: 1407-1414
- Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis.J Hepatol. 2015; 63: 1272-1284
- Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.Gastroenterology. 2007; 133: 825-834
- Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites.Gastroenterology. 2017; 152: 157-163
- Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.Hepatology. 2010; 51: 1675-1682
- Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites.J Hepatol. 2013; 59: 482-489
- Acute kidney injury in decompensated cirrhosis.Gut. 2013; 62: 131-137
- Renal Failure and cirrhosis: a systematic review of mortality and prognosis.J Hepatol. 2012; 56: 810-818
- Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.Hepatology. 2002; 35: 140-148
- Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections.Am J Gastroenterol. 2017; 112: 1575-1583
- Infections in patients with cirrhosis increases mortality four-fold and should be used in determining prognosis.Gastroenterology. 2010; 139: 1246-1256
- Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol. 2007; 5: 938-945
- Prognosis of untreated hepatocellular carcinoma.Hepatology. 2015; 61: 184-190
- Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.Gastroenterology. 2013; 144: 1426-1437
- Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis.J Hepatol. 2017; 67: 1177-1184
- Clinical states of cirrhosis and competing risks.J Hepatol. 2018; 68: 563-576
- Noninvasive methods to assess liver disease in patients with hepatitis B or C.Gastroenterology. 2012; 142: 1293-1302
- Elastography in the non-invasive evaluation of the extent of fibrosis and in the diagnosis of portal hypertension.in: Proceedings of the Fifth Baveno International Consensus Workshop. de Franchis R. Wiley-Blackwell, Oxford, UK2011: 18-27 (edit.)
- Patients with Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis.Clin Gastroenterol Hepatol. 2019; 17: 2101-2109
- Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension.J Hepatol. 2015; 63: 743-752
- Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease.PLoS ONE. 2014; 9: e95776
- Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.Gastroenterology. 2008; 134: 960-974
- Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.N Engl J Med. 2005; 353: 2254-2261
- Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.Gastroenterology. 2007; 133: 481-488
- Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.J Hepatol. 2010; 53: 762-768
- Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.Hepatology. 2007; 46: 922-938
- Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding.Liver International. 2017; 37: 707-716
- Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.J Hepatology. 2018; 69: 878-885
- Ruling out esophageal varices in NAFLD cirrhosis: can we do without endoscopy?.J Hepatology. 2018; 69: 769-771
- Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.Am J. Gastroenterol. 2019; 114: 446-452
- Portal pressure, presence of gastroesophageal varices and variceal bleeding.Hepatology. 1985; 5: 419-424
- Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings.Gastroenterology. 1998; 114: 1296-1303
- Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension.Gastroenterology. 2017; 152: 1358-1365
- Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis.QJM. 1998; 91: 19-25
- The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.Hepatology. 2000; 32: 930-934
- Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.J Gastroenterol. 2011; 46: 687-695
- Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.J Hepatol. 2018; 68: 949-958
- Prognostic value of early measurements of portal pressure in acute variceal bleeding.Gastroenterology. 1999; 117: 626-631
- Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.Hepatology. 2004; 40: 793-801
- Spanish Cooperative Group for Portal Hypertension and Variceal Bleeding. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy.J Hepatol. 2008; 48: 229-236
- Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.Am J Gastroenterol. 2006; 101: 506-512
- Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.Am J Gastroenterol. 2012; 107: 418-427
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.Hepatology. 2002; 36: 1367-1373
- Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: an Open Randomized Controlled Pilot Study.Gut Liver. 2017; 11: 702-710
- Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.Gastroenterology. 2013; 144: 102-111
- Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.Gastroenterology. 2018; 154: 1694-1705
- Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding.N Engl J Med. 2010; 362: 2370-2379
- Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.Hepatology. 2019; 69: 1287-1299
- Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.J Hepatol. 2016; 65: 692-699
- β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.Lancet. 2019; 393: 1597-1608
- Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults.Cochrane Database Syst Rev. 2012; 8CD004544
- Effects of an intensive lifestyle intervention Program on portal hypertension in patients with Cirrhosis and obesity: the sportdiet study.Hepatology. 2017; 65: 1293-1305
- EASL Clinical Practice Guidelines: management of alcohol-related liver disease.J Hepatol. 2018; 69: 154-181
- Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: a Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2017; 15: 1521-1530
- European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol. 2016; 64: 1388-1402
- Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.J Hepatol. 2017; 66: 610-618
- Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.Hepatology. 2010; 51: 1675-1682
- Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease.Am J Med. 1968; 44: 406-420
- Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study.Gastroenterology. 1996; 111: 701-709
- Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.J Hepatol. 2016; 64: 1217-1223
- Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.Gastroenterology. 2016; 151: 130-139
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.Gastroenterology. 2017; 153: 1273-1283
- Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol. 2016; 65: 741-747
- Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.Gastroenterology. 2018; 155: 411-421
- Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.J Hepatol. 2019; 71: 265-273
- Newly diafnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study.J Hepatol. 2018; 69: 345-352
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol. 2017; 67: 370-398
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.Lancet. 2013; 381: 468-475
- The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study.J Hepatol. 2015; 63: 1118-1125
- Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.Aliment Pharmacol Ther. 2018; 48: 431-439
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Hepatology. 2017; 66: 1444-1453
- Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis.Hepatology. 2016; 63: 284-306
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.J Hepatol. 2018; 68: 1129-1136
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.Hepatology. 2012; 56: 532-543
- Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.J Hepatol. 2009; 51: 468-474
- Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.Clin Gastroenterol Hepatol. 2015; 13: 1846-1853
- Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol. 2017; 66: 485-493
- The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.Antivir Ther. 2011; 16: 677-684
- Gruppo Triveneto per l'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.Gastroenterology. 2004; 127: 476-484
- Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial.Hepatol Int. 2013; 7: 248-256
- Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.Gut. 2017; 66: 1838-1843
- Hepatic venous pressure gradient (HVPG) predicts clinical disease progression in patients with compensated cirrhosis due to NASH.Hepatology. 2017; 66: 244A
- Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB).J. Hepatol. 2017; 66: S97-S98
- Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C.Ann Intern Med. 2008; 149: 399-403
- Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.Gastroenterology. 2009; 136: 1651-1658
- Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis.Gastroenterology. 2016; 150: 430-440
- Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med. 2004; 351: 1521-1531
- Efficacy and safety of peginterferon alfa 2a(40 KD) plus ribavirin in hepatitis c patients with advanced fibrosis and cirrhosis.Hepatology. 2010; 51: 388-397
- Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.JAMA. 2012; 308: 2584-2593
- North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study.N Engl J Med. 1988; 319: 983-989
- Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis.Can J Gastroenterol. 2011; 25: 147-155
- Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.Hepatology. 2009; 50: 825-833
- Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.J Hepatol. 2014; 60: 757-764
- Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding.Am J Gastroenterol. 2005; 100: 797-804
- Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.Gastroenterology. 2009; 137: 119-128
- Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.Gut. 2013; 62: 1634-1641
- Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients.Am J Gastroenterol. 1993; 88: 514-519
- Hepatic hydrothorax. Clinical features, management, and outcomes in 77 patients and review of the literature.Medicine (Baltimore). 2014; 93: 135-142
- Hepatic hydrothorax: an update and review of the literature.World J Hepatol. 2017; 9: 1197-1204
- CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.J Hepatol. 2014; 61: 1038-1047
- The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.J Hepatol. 2015; 62: 831-840
- The MELD score in patients awaiting liver transplant: strengths and weaknesses.J Hepatol. 2011; 54: 1297-1306
- Transfusion strategies for acute upper gastrointestinal bleeding.N Engl J Med. 2013; 368: 11-21
- Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients.Lancet. 1995; 346: 865-868
- Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial.Lancet. 1997; 350: 1495-1499
- Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study.Dig Liver Dis. 2001; 33: 41-48
- Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.Cochrane Database Syst Rev. 2010; 9CD002907
- Management of infections in cirrhotic patients: report of a consensus conference.Dig Liver Dis. 2014; 46: 204-212
- Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial.Hepatology. 2005; 41: 588-594
- Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage.Gastrointest Endosc. 2003; 57: 58-61
- Association of prophylactic endotracheal intubation in critically ill patients with upper GI bleeding and cardiopulmonary unplanned events.Gastrointest Endosc. 2017; 86: 500-509
- Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study.J Hepatol. 2012; 57: 1207-1213
- PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding.J. Hepatol. 2019; 70: e16-e17
- Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices.Ann Intern Med. 1993; 119: 1-7
- Varices and Variceal Hemorrhage in Cirrhosis: a New View of an Old Problem.Clin Gastroenterol Hepatol. 2015; 13: 2109-2117
- Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials.J Gastroenterol Hepatol. 2016; 31: 1519-1526
- Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: an Observational Study.Hepatology. 2019; 69: 282-293
- Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.Gut. 2019; 68: 1297-1310
- Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.J Hepatol. 2017; 68: 73-81
- Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis.Hepatology. 2004; 39: 1623-1630
- Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review.Liver Int. 2014; 34: 823-833
- Factors predicting success of endoscopic variceal ligation for seconary prophylaxis of esophageal variceal bleeding.J Gastroenterol Hepatol. 2006; 21: 237-241
- Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.Am J Gastroenterol. 2007; 102: 1116-1126
- Beta adrenergic blockade and decompensated cirrhosis.J Hepatol. 2017; 66: 849-859
- A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.Hepatology. 2017; 65: 1693-1707
- Prevention of Rebleeding From Esophageal Varices in Patients with Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy.Gastroenterology. 2015; 149: 660-668
- Prevalence, classification and natural history of gastric varices: a long-term follow-upstudy in 568 portal hypertension patients.Hepatology. 1992; 16: 1343-1349
- Vascular anatomy and the morphologic and hemodynamic classifications of gastric varices and spontaneous portosystemic shunts relevant to the BRTO procedure.Tech Vasc Interv Radiol. 2013; 16: 60-100
- Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration.J Gastroenterol Hepatol. 1996; 11: 51-58
- Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.J Hepatol. 2011; 54: 1161-1167
- Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension.Cochrane Database Syst Rev. 2015; 5CD010180
- Endoscopic cyanoacrylate injection vs. beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial.Gut. 2010; 59: 729-735
- Cost-effectiveness of N-butyl-2-cyanoacrylate (histoacryl) glue injections vs. transjugular intrahepatic portosystemic shunt in the management of acute gastric variceal bleeding.Am J Gastroenterol. 2003; 98: 2688-2693
- A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding.Endoscopy. 2007; 39: 679-685
- Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: review and Meta-Analysis.Dig Dis Sci. 2015; 60: 1543-1553
Runyon B.A. Management of adult patients with ascites due to cirrhosis: update 2012. www.aasld.org
- The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.Hepatology. 2003; 38: 258-266
- Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.Hepatology. 1996; 23: 164-176
- The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis.Dig Liv Dis. 2019; 51: e43
- Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.Gastroenterology. 1983; 84: 961-968
- Hepatorenal disorders: role of the renin-angiotensin-aldosterone system.Semin Liver Dis. 1994; 14: 23-34
- Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites.Digestion. 1985; 31: 189-193
- Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance.Eur J Clin Invest. 1990; 20: 111-117
- A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.Hepatology. 1991; 14: 231-236
- Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.Gastroenterology. 1983; 84: 961-968
- Combined vs. sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.Gut. 2010; 59: 98-104
- Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.J Hepatol. 2003; 39: 187-192
- Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content.Liver. 1993; 13: 156-162
- Salt or no salt in the treatment of cirrhotic ascites: a randomised study.Gut. 1986; 27: 705-709
- Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study.Liver Int. 2015; 35: 1508-1515
- Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.Lancet. 2018; 391: 2417-2429
- Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.Liver Int. 2019; 39: 98-105
- Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.J Hepatol. 2018; 69: 1250-1259
- ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.J Hepatol. 2021; 74: 340-349
- Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis.Gastroenterology. 2019; 157: 149-162
- Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists.J Hepatol. 1996; 25: 135-144
- A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.N Engl J Med. 2000; 342: 1701-1707
- Transjugular intrahepatic portosystemic shunting vs. paracentesis plus albumin for refractory ascites in cirrhosis.Gastroenterology. 2002; 123: 1839-1847
- The North American study for the treatment of refractory ascites.Gastroenterology. 2003; 124: 634-641
- Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites.Hepatology. 2004; 40: 629-635
- Transjugular intrahepatic portosystemic shunt vs. paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.J Gastroenterol. 2011; 46: 78-85
- A metaanalysis of transjugular intrahepatic portosystemic shunt vs. paracentesis for refractory ascites.J Hepatol. 2005; 43: 990-996
- Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.Gastroenterology. 2005; 129: 1282-1293
- Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.Liver Int. 2005; 25: 349-356
- TIPS vs. paracentesis for cirrhotic patients with refractory ascites.Cochrane Database Syst Rev. 2006; CD004889
- Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.Gastroenterology. 2007; 133: 825-834
- TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.World J Gastroenterol. 2014; 20: 2704-2714
- Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis.J Clin Gastroenterol. 2014; 48: 290-299
- Improved clinical outcome using polytetrafluoroethylene- coated stents for TIPS: results of a randomized study.Gastroenterology. 2004; 126: 469-475
- Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites.Gastroenterology. 2017; 152: 157-163
- Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites.Clin Gastroenterol Hepatol. 2018; 16: 1503-1510
- Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.J Hepatol. 2017; 67: 508-516
- Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis.Clin Gastroenterol Hepatol. 2018; 16: 1153-1162
- Transjugular Intrahepatic Portosystemic Shunt Using the New Gore Viatorr Controlled Expansion Endoprosthesis: prospective, Single-Center, Preliminary Experience.Cardiovasc Intervent Radiol. 2019; 42: 78-86
- AISF TIPS Special Conference. Consensus conference on TIPS management: techniques, indications, contraindications.Dig Liver Dis. 2017; 49: 121-137
- ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.Liver Int. 2018; 38: 1036-1044
- Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study.J Hepatol. 2013; 58: 922-927
- Alfapump system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study.J Hepatol. 2017; 67: 940-949
- Patients with refractory ascites treated with Alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.Qual Life Res. 2018; 27: 1513-1520
- Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites.Liver Transpl. 2017; 23: 583-593
- Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis.Aliment Pharmacol Ther. 2017; 46: 981-991
- The evaluation of renal function and disease in patients with cirrhosis.J Hepatol. 2010; 52: 605-613
- New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?.Liver Int. 2015; 35: 2108-2114
- Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex.J Hepatol. 2019; 70: 847-854
- Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and management of Chronic Kidney Disease.Kidney Int. (suppl.). 2013; 3: 1-150
- National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Ann Intern Med. 2003; 139: 137-147
- Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.J Hepatol. 2015; 62: 968-974
- Significance of oliguria in critically ill patients with chronic liver disease.Hepatology. 2017; 66: 1592-1600
- Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.Hepatology. 2003; 37: 233-243
- Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.J Hepatol. 2012; 57: 267-273
- Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.Hepatology. 2014; 60: 622-632
- Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: a Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2017; 15: 1003-1013
- Neuthrophil Gelatinase-Associatted Lipocalin for assessment of acute kidneu injury in cirrhosis: a prospective studies. urine NGAL. Relevance for the differential diagnosis and clinical outcomes.Hepatology. 2019; 70: 319-333
- Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.Gastroenterology. 2002; 122: 923-930
- Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.Hepatology. 2002; 36: 941-948
- A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome.Gastroenterology. 2008; 134: 1360-1368
- Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.Gastroenterology. 2008; 134: 1352-1359
- REVERSE Study Investigators Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.Gastroenterology. 2016; 150: 1579-1589
- Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.J Hepatol. 2014; 60: 955-961
- Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.Hepatology. 2015; 62: 567-574
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study.Hepatology. 2016; 63: 983-992
- Terlipressin for hepatorenal syndrome.Cochrane Database Syst Rev. 2012; CD005162
- Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2017; 2: 94-102
- Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.J Hepatol. 2007; 47: 499-505
- Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.Hepatology. 2002; 36: 374-380
- Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.J Hepatol. 2012; 56: 1293-1298
- An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.Am J Gastroenterol. 2008; 103: 1689-1697
- Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.Hepatology. 2020; 71: 600-610
- Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.Dig Dis Sci. 2007; 52: 742-748
- Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy.Kidney Int. 2005; 68: 362-370
- Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis.Ren Fail. 1995; 17: 135-146
- Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.Int Urol Nephrol. 2014; 46: 793-800
- Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications.Liver Int. 2017; 37: 843-850
- The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations.J Hepatol. 2018; 69: 803-809
- Early renal replacement therapy in patients with postoperative acute liver failure associated with acute renal failure: effect on postoperative outcomes.J Am Coll Surg. 2007; 205: 266-276
- Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.N Engl J Med. 2016; 375: 122-133
- Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: the ELAIN Randomized Clinical Trial.JAMA. 2016; 315: 2190-2199
- Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.J Hepatol. 2012; 57: 1135-1140
- A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: toward a "Blended Principle Model".Am J Transplant. 2015; 15: 2552-2561
- Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.Liver Transpl. 2011; 17: 1328-1332
- Impact of pretransplant renal function on survival after liver transplantation.Transplantation. 1995; 59: 361-365
- Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.J Hepatol. 2004; 40: 140-146
- Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes.Liver Transpl. 2015; 21: 1347-1354
- Simultaneous Liver-Kidney Allocation Policy: a Proposal to Optimize Appropriate Utilization of Scarce Resources.Am J Transplant. 2016; 16: 758-766
- Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis.J Hepatol. 2015; 62: S131-S143
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.Intensive Care Med. 1996; 22: 707-710
- Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.Gut. 2018; 67: 1870-1880
- Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.J Hepatol. 2019; 70: 398-411
- Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.Gastroenterology. 2018; 156: 1368-1380
- Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.Hepatology. 2015; 62: 243-252
- Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation.Gastroenterology. 2019; 156: 1381-1391
- Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients.Hepatology. 2019; 70: 334-345
- Acute-on-chronic liver failure in patients with alcohol-related liver disease.J Hepatol. 2019; 70: 319-327
- Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure.Gastroenterology. 2012; 142: 505-512
- Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure.World J Gastroenterol. 2013; 19: 1104-1110
- Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.Stem Cells Transl Med. 2012; 1: 725-731
- Spontaneous Bacterial Peritonitis.Clin Infect Dis. 1998; 27: 669-6764
- Spontaneous peritonitis and bacteremia in Laennec's Cirrhosis Caused by Enteric Organisms. A Relatively Common but Rarely Recognized Syndrome.Ann Intern Med. 1964; 60: 568-580
- Immune Dysfunction and Infections in Patients With Cirrhosis.Clin Gastroenterol Hepatol. 2011; 9: 727-738
- Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites.J Hepatol. 1997; 26: 1372-1378
- Pathological bacterial translocation in liver cirrhosis.J Hepatol. 2014; 60: 197-209
- Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis.World J Gastroenterol. 2009; 15: 3845-3850
- Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis.Gastroenterology. 1990; 98: 127-133
- Optimization of ascitic fluid culture technique.Gastroenterology. 1988; 95: 1351-1355
- Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.J Hepatol. 2014; 60: 1310-1324
- The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial.Hepatology. 2016; 63: 1299-1309
- Antibiotic stewardship and empirical antibiotic treatment: how can they get along?.Dig Liver Dis. 2017; 49: 579-584
- Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis.Liver Int. 2019; 39: 1448-1458
- A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.J Dig Dis. 2014; 15: 260-267
- Rifaximin treatment in hepatic encephalopathy.N Engl J Med. 2010; 362: 1071-1081
- Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.Eur J Gastroenterol Hepatol. 2016; 28: 1450-1454
- Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma.Dig Liver Dis. 2017; 49: 440-445
- Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.J Hepatol. 2009; 51: 682-689
- Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review.Transplantation. 2012; 94: 1145-1153
- Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.Liver Int. 2012; 32: 919-927
- Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis.Radiology. 2012; 265: 124-132
- The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors.Am J Gastroenterol. 2012; 107: 1872-1878
- Liver: PVT in cirrhosis, not always an innocent bystander.Nat Rev Gastroenterol Hepatol. 2015; 12: 11-13
- IRSVT study investigators. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis.Clin Transl Gastroenterol. 2018; 9: 176
- BO-LIVES (BOlogna LIVEr vascular Studies). Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis.Am J Gastroenterol. 2019; 114: 258-266
- Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: a Systematic Reviewand Meta-analysis.Gastroenterology. 2017; 153: 480-487
- A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis.Eur J Gastroenterol Hepatol. 2019; 31: 34-42
- Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis.Clin Gastroenterol Hepatol. 2012; 10: 776-783
- Vascular diseases of the liver.J Hepatol. 2016; 64: 179-202
- The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2018; 30: 1187-1193
- Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.Gut. 2011; 60: 846-852
- Endovascular treatment for nonacute symptomatic portal venous thrombosis through intrahepatic portosystemic shunt approach.J Vasc Interv Radiol. 2011; 22: 61-69
- Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis.Aliment Pharmacol Ther. 2019; 49: 20-30
- Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation.Aliment Pharmacol Ther. 2006; 23: 767-775
- Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications.Eur Radiol. 2015; 25: 3431-3437
- Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: final Analysis of a 61-Patient Cohort.J Vasc Interv Radiol. 2017; 28: 1714-1721
- How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists.J Hepatol. 2013; 59: 257-264
- Palliative care in decompensated cirrhosis: a review.Liver Int. 2018; 38: 768-775
- Management of liver cirrhosis between primary care and specialists.World J Gastroenterol. 2011; 17: 2273-2282
Article info
Publication history
Published online: July 26, 2021
Accepted:
June 20,
2021
Received:
March 8,
2021
Identification
Copyright
© 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
